Role of E6AP in Malignancies and Tumorigenesis

situation of E6AP in Malignancies and Tumori agentsisINTRODUCTIONLeukemia is a malignant hematological disorder characterized by proliferation of ab blueprint white carrells that infiltrate the bone marrow, peripheral blood and oppo send beta organs. Leukemia arising from myeloid cells is known as Myeloid Leukemia which may each(prenominal) be chronic myeloid leukemia (CML) and/or acute myeloid leukemia (AML). AML is a complex disease caused by mutations, deregulated constituent reflectivity and epigenetic modifications leading to increase proliferation and reduced contraryiation of hematopoietic progenitor cells. Several important molecular(a) markers urinate been discovered in AML to better characterize patients. C/EBP is an important regulator of Granulopoiesis. Several groups have reported mutations in the C/EBP gene in a subset of patients with AML presenting with normal karyotypes. A pregnant percentage of AML patients without chromosomal translocations have demonstr ated abnormalities in C/EBP protein or function, suggesting that loss of transcriptional make is a common mechanism of leukemogenesis. Even in the setting of an another(prenominal)(prenominal) proleukemogenic genetic abnormalities, such as the (8 21) translocation, C/EBP has been demonstrated to be aberrantly regulated, in this case by down ordination of mental synthesis. Functional alterations of C/EBP in AML include mutations of the C/EBP gene and deregulated expression of C/EBP by chromosomal translocations. Further, post-transcriptional or post-translational suppression of C/EBP has been demonstrated to be involved in hematopoietic malignancies. AML is also characterized as, a malignant disease of hematopoietic clay in which cells accumulate in an un distinctiated state due to mutations that close out their normal differentiation and allow undifferentiated cells to survive and proliferate. The molecular changes that choke in AML usually lead to either abnormal cell prolif eration (FLT3 and reticular activating system mutations) or block in differentiation (AML1/ETO, PML/RAR alpha, C/EBPalpha mutations) or suppression of apoptosis (bcl2 overexpression). Despite of block in differentiation, native AML cells often surface some morphological signs of differentiation that allow a classification into different subsets, and further differentiation may be induced by movie to various soluble mediators, e.g., all trans-retinoic paneling (ATRA) and several(prenominal) cytokines in t(1517).All-trans retinoic battery-acid (ATRA) is a derivative of vitamin A and it affects cellular development including haematopoiesis, in incident granulocytic differentiation. ATRA could induce a dose- symbiotic differentiation of HL-60 promyeloblasts to mature, functioning neutrophils. ATRA induces growth forbidding, differentiation, and apoptosis in cancer cells, including acute promyelocytic leukemia (APL). In APL, expression of promyelocytic leukemia protein retinoic aci d sensory receptor (PMLRAR) fusion protein, owing to the t (15 17) reciprocal translocation, leads to a block in the promyelocytic stage of differentiation.E3 Ubiquitin ligases are a large family of proteins engaged in the regulation of protein turnover and activity through a multistep proteolytic come down, called ubiquitination. Ubiquitination of a maneuver protein involves 2 distinct steps covalent attachment of denary ubiquitin molecules to the protein substrates and adulteration of the polyubiquitylated proteins by the 26S proteasome system. The first step is interfered by a cascade of 3 enzymes ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3) 1, 2. Ubiquitin is a 76- aminic acid polypeptide that is highly conserved among eukaryotic organisms. It is first activated in an ATP- babelike manner via prevailing to E1 through a thioester bond among a cysteine counterweight at the active site of E1 and the C-terminal glycine (G76 ) of ubiquitin. Activated ubiquitin in an E1-ubiquitin complex is then transferred to E2, which also participates in the make-up of a thioester bond between its active site cysteine residue and the G76 of ubiquitin. Finally, ubiquitin is covalently attached to the derriere protein through an is opeptide bond between the G76 of ubiquitin and the -amino group of an informal lysine residue of the target protein, in a reaction catalyzed by E3 ligase. later(prenominal) to the linkage of ubiquitin to the target protein, a polyubiquitin chain is formed in which the C-terminus of each ubiquitin moiety is linked to a specific lysine residue (most comm simply Lys48) of the former ubiquitin to form K48-linked polyubiquitylated conjugates which are rapidly recognized by the 19S regulatory subunit of the 26S proteasome and degraded by the 20S core particle 1-3.There are just about 600 E3 ligases in the human genome that can be classify into 3 major(ip) types the N-end endure ubiquitin l igases HECT-type and the RING-type, on the basis of domain structure and substrate perception1.The N-end rule ubiquitin E3 ligases target protein substrates bearing specific destabilizing N-terminal residues, including Arg, Lys, His (type I) and Phe, Trp, Leu, Tyr, Ile (type II)1.The second type HECT (homology to E6AP C-Terminus) E3-ubiquitin protein ligases, found from barm to humans range in size from 80kDa to more than 500kDa. They are characterised by the HECT domain, a C-terminal region of approximately 350 amino acids in length with significant similarity to C-terminus of E6AP. Unlike RING E3s which act as scaffolds facilitating interaction between E2s and substrates, HECT E3 ligases form an intermediate thioester bond with the ubiquitin C-terminus through an evolutionarily conserved cysteine residue onward catalyzing substrate ubiquitination. Hence, HECT E3s play a direct catalytic role in the final attachment of ubiquitin moieties to target proteins. The N-terminus is hig hly variable and may be involved in substrate recognition. On the basis of distinct amino acid sequence motifs within the N-terminus, human HECT E3s can be classified into 3 sub-families HECT E3s with RLDs (RCC1-like domains, termed as HERC (HECT and RCC-1like domain E3s), HECT E3s with WW domains (called Nedd4/Nedd4- like E3s), and HECT E3s that neither contain RLDs nor WW domains (called SI(ngle)- HECT E3s). E6AP, the picture of HECT E3 family belongs to the third sub-family of HECT E3 ligases 3-5.The third and the largest type of E3 ligase is the RING (Really Interesting New Gene) family. RING-based E3 ligases are specified by over 600 human genes surpassing 518 protein kinase genes. These are characterised by a classic C3H2C3 or C3HC4 RING finger domain with a characteristic linear sequence Cys-X2-Cys-X9-39-Cys-X1-3-His-X2-3-Cys/His-X2-Cys-X4-48-Cys-X2-Cys, where X can be every amino acid. The RING domain provides a docking site for the E2 enzyme, which mediate transfer of ubiq uitin to the substrate, facilitating assembly of mono- or polyubiquitylated conjugates via different lysine residues of ubiquitin. The resulting modifications have a diverse range of biological functions, from proteasome-dependent proteolysis (Lys48- and Lys 11-linked polyubiquitin) to post-translational regulation of protein function, structure, assembly, and/or localization (Lys 63 and other linkages)1, 6.E3 ligases can also be classified into single subunit E3s (e.g. Mdm2, Cbl) and multi-subunit complexes (APC, SCF). E3 enzymes bind their target substrates through various protein-protein interaction domains (e.g. WD 40 repeats). However, for substrate recognition post-translational modifications such as phosphorylation or proteolytic cleavage are required7. The limited motif in the substrate is called degron. There are many different types of degrons (e.g. phosphodegron, PEST). Once modified, a degron in a substrate might be recognized by a specific E3 ligase, which forms the ba sis for its subsequent ubiquitination8.through and through ubiquitin-mediated covalent modification of diverse range of cellular proteins, E3 ubiquitin ligases regulate several cellular functions or biological processes such as cell one shot progression, Oncogenesis, signal transduction, transcription regulation, DNA repair, endocytois, transport and development via proteolytic or non-proteolytic mechanisms 2, 9.A direct molecular link between cell-cycle tally, Oncogenesis and E3 ubiquitin ligase activity was support by several clinical findings and wealth of experimental data on E6AP, SKP2 and FBW7, Nedd 4-1, Pirh2, CDC20, CDH1 and also on other E3 ligases 3, 10, 11.Understanding the physiological role of E6-AP, the innovation member of the HECT E3 family, is of interest because inactivation of UBE3A gene encoding E6AP has been associated with Angelman Syndrome, a transmittable neurological disorder. Moreover, in the case of cervical cancer, the E6/E6-AP complex not only targe ts p53 for ubiquitin-mediated adulteration, but also targets other proteins, which is necessary for HPV-induced cervical carcinogenesis12. E6-AP forms a changeless complex with the adaptor protein E6. The dimeric complex binds to and targets p53 for ubiquitin-mediated proteolysis, thus eventually interfering with the damaging growth regulating activities of this tumor suppressor protein 13-15. In addition, the expression of E6-AP protein is decreased in human invasive breast and prostate cancers compared with their adjacent normal tissues. This down-regulation of E6-AP is accompanied by the elevation of ER in breast and AR in prostate carcinomas16. Furthermore, in vivo data from E6-AP-knockout animals indicated that the expression levels of ER and AR are increased in E6-AP-null mammary and prostate glands, respectively, when compared with that of normal control animals, suggesting that E6-AP modulates the protein levels of ER in breast and AR in prostate glands 17.E6AP, a 100-kDa cellular protein is a member of functionally related E3-ubiquitin-protein ligases defined by the domain homologous to the carboxy terminus hect domain.20 E3 ligases ubiquitinate and degrade several regulatory proteins including p53, p27, promyelocytic leukemia retinoic acid receptor and others, which serve as tumor suppressors and cell-cycle inhibitors.E6AP promotes C/EBP ubiquitination leading to its proteasome-mediated abjection and thus functional inactivation. E6AP negatively regulate Granulopoiesis by targeting C/EBP for degradation via ubiquitin proteasome pathway.Promyelocytic leukemia tumor suppressor (PML) has been recently place as a target of catalytically active form of E6AP. PML tumor suppressor is essential for the formation of PML nuclear bodies. Recent studies have implicated role of PML and PML nuclear bodies in the regulation of growth inhibition, senescence and apoptosis. PML is down regulated in multiple human cancers and experimental data has correlated redu ced PML activity and expression to E3 ubiquitin ligase activity of E6AP, regulating protein turnover and activity18.Recently, Annexin I involved in the inhibition of cell proliferation, regulation of cell differentiation, anti-inflammatory effects, cell death signalling, carcinogenesis has been identified as a novel target of E6AP in addition to pure substrates, including p53 tumor suppressor, PDZ domain-containing protein scribble, a transcriptional repressor of the gene encoding hTERT19. In addition, studies have also implicated the role of E6AP ubiquitin ligase activity in ubiquitin-dependent degradation of Peroxiredoxin1 and presumptively open avenues to investigate the functional link between lack of E6AP expression and stability of Peroxiredoxin 1with regard to the pathogenesis of Angelman syndrome20.p53 is targeted for proteasomal degradation by mdm2 which is a p53 target gene containing E3 ubiquitin ligase activity21. While mdm2 targets p53 for degradation, mdm2 is self -u biquitinated and degraded. Cyclin dependent kinase inhibitor p21waf/cip, another p53 target gene, is degraded by proteasome and GSK3 (glycogen synthase kinase 3) mediated phosphorylation 22. Rb (Retinoblastoma) protein is a tumor suppressor and negatively regulates G1/S transition by interacting with E2F transcription factor. Rb protein is degraded in an ubiquitin dependent manner 23. In addition, free E2F is also degraded in ubiquitin dependent manner by the 26S proteasome. Thus, collectively HECT domain containing E3 ligases are important for homeostasis of protein levels and defects in their function may lead to various diseases including cancer.Thus, wealth of experimental data and clinical findings identifying many substrates targeted by E3 ubiquitin ligases, indicate that the deregulation of Ubiquitin proteasome system in cell cycle control is tightly linked to malignancies and tumorigenesis.Due to the supra relevance and role of E6AP in malignancies and tumorigenesisThe proje ct is based on the expression, subtlety and validation of GST tagged protein that is GST- E6AP.The current study includesCell culture HL-60 cells, a human promyelocytic leukemia cell line. HL-60 cells treated with 1uM ATRA for 0,24 and 48 hours.GST- E6AP Protein expression and purificationGST-E6AP rupture downObjectives 1) Expression of GST and GST-E6AP plasmids in BL21 strain of E.Coli2) Purification of GST and GST-E6AP proteins from BL21 strain of E.Coli3) organization of expression through western blotting4) To detect GST-E6AP protein interaction with whole cell lysates of HL-60 cells treated with 1M ATRA for 0, 24 and 48 hrs GOMTI NAGAR EXTENSION, LUCKNOW